Achilles Material Acquisition Platform
Research type
Research Study
Full title
Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT)
IRAS ID
233696
Contact name
Vicky Diment
Contact email
Sponsor organisation
AstraZeneca
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Achilles Therapeutics is performing a research study that involves the collection of patient tumour and blood samples to conduct research to develop and optimise (make it the best it can be) new treatments and methods in the area of “immunotherapy”. Immunotherapy is the prevention or treatment of diseases with substances that stimulate an immune response. Immunotherapy methods have been used to target specific markers on cancer tumour cells that are absent in normal healthy cells. There are various clinical trials ongoing in this area. The doctors and scientists at University College London (UCL) are investigating a way to take immune cells from inside a patient’s tumour, modify them and increase the numbers of these cells, which recognise and kill specifically the cancer cells in the tumour. It has been shown that this can work in the research lab but, to make it into a new treatment, the manufacturing process needs to be developed and optimised. Achilles Therapeutics has been set up to do this. This study will be taking samples from cancer patients who have agreed to take part, and will be using these samples in the development and manufacturing of a potential new immunotherapy for cancer patients.\n
REC name
London - Hampstead Research Ethics Committee
REC reference
17/LO/1755
Date of REC Opinion
17 Oct 2017
REC opinion
Favourable Opinion